EUVIMEDEUVIMED entdecken
Crossref

Сirculating DNA markers for assessing antitumor therapy efficacy and monitoring metastatic colorectal cancer

Anastasia Ponomaryova, Dmitry Kostromitsky, Anna Tarasova, Elena Rykova, Alexey Dobrodeev, Ulyana Zhilenkova, Sergey Afanasiev, Nadezhda Cherdyntseva

Eurasian Journal of Medicine and Oncology · 26.08.2026 · 10 (5) · 026120133

DOI: 10.36922/ejmo026120133 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Eurasian Journal of Medicine and Oncology, online erschienen am 26.08.2026. Verfasst von Anastasia Ponomaryova und 7 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Colorectal cancer remains one of the leading causes of oncological morbidity and mortality. Aberrant methylation patterns of tumor-suppressor genes and oncogenes have been detected in circulating DNA isolated from the blood of cancer patients, suggesting their potential utility as diagnostic and prognostic markers.

Objective

To evaluate changes in the methylation levels of VIM, SEPTIN9, and DCC genes in cell-surface-bound cell-free DNA (csb-cfDNA) from the blood of metastatic colorectal cancer (mCRC) patients after antitumor treatment over a long-term follow-up period.

Methods

Blood samples were collected from mCRC patients (n = 21) at baseline, after three courses of preoperative chemotherapy (FOLFOXIRI regimen), 10–15 days post-surgery, and every three months during follow-up. The methylation levels of VIM, SEPTIN9, and DCC genes were quantified by methylation-specific polymerase chain reaction.

Results

Preoperative chemotherapy and tumor resection were each associated with a significant decrease in SEPTIN9 and VIM methylation levels in csb-cfDNA compared to baseline (2.3-fold and 2.0-fold, respectively; p ≤ 0.05). DCC methylation decreased 1.5-fold after surgery relative to pre-treatment levels (p ≤ 0.05). During follow-up after completion of combined treatment, methylation levels of SEPTIN9, VIM, and DCC remained stable in mCRC patients without signs of disease progression (n = 8), showing no significant change from post-surgical values (days 10–15). In contrast, mCRC patients with disease progression (n = 13) exhibited increased methylation levels of SEPTIN9, VIM and DCC compared to post-resection values.

Conclusion

These findings indicate that monitoring VIM, DCC, and SEPTIN9 methylation levels in csb-cfDNA has potential for evaluating the effectiveness of antitumor therapy and for early detection of relapses in mCRC patients during the follow-up period.

Zitieren

APA

Ponomaryova, A., Kostromitsky, D., Tarasova, A., Rykova, E., Dobrodeev, A., Zhilenkova, U., Afanasiev, S., & Cherdyntseva, N. (2026). Сirculating DNA markers for assessing antitumor therapy efficacy and monitoring metastatic colorectal cancer. Eurasian Journal of Medicine and Oncology, 10(5), 026120133. https://doi.org/10.36922/ejmo026120133

Vancouver

Ponomaryova A, Kostromitsky D, Tarasova A, Rykova E, Dobrodeev A, Zhilenkova U, et al. Сirculating DNA markers for assessing antitumor therapy efficacy and monitoring metastatic colorectal cancer. Eurasian Journal of Medicine and Oncology. 2026;10(5):026120133. doi:10.36922/ejmo026120133

BibTeX
@article{Ponomaryova2026,
  author = {Ponomaryova, Anastasia and Kostromitsky, Dmitry and Tarasova, Anna and Rykova, Elena and Dobrodeev, Alexey and Zhilenkova, Ulyana and Afanasiev, Sergey and Cherdyntseva, Nadezhda},
  title = {Сirculating DNA markers for assessing antitumor therapy efficacy and monitoring metastatic colorectal cancer},
  journal = {Eurasian Journal of Medicine and Oncology},
  year = {2026},
  volume = {10},
  number = {5},
  pages = {026120133},
  doi = {10.36922/ejmo026120133}
}
Kostenlos starten →